The global transcatheter mitral valve market is on an impressive growth trajectory, expected to achieve a valuation of USD 1.6 billion by the end of 2024 and expand to USD 3.0 billion by 2034. This robust expansion, marked by a compound annual growth rate (CAGR) of 10.8%, underscores the increasing demand for advanced cardiac interventions.
Driving this substantial growth are two primary factors: the aging global population and the rising prevalence of mitral valve regurgitation. As one of the most common valve diseases worldwide, mitral regurgitation requires sophisticated medical solutions, positioning transcatheter mitral valve replacement (TMVR) as a crucial advancement in the field of transcatheter therapeutics.
Despite the challenges associated with transcatheter mitral valve procedures—such as the precise positioning of the valve, the anchoring technique, and the potential for left ventricular outflow tract obstruction—significant advancements in transapical and transseptal devices are enhancing clinical outcomes. These innovations are supported by ongoing feasibility trials worldwide, reflecting a strong commitment to improving patient care and driving forward the standards of cardiac treatment.
The transcatheter mitral valve market is not only expanding but also revolutionizing the treatment landscape for mitral regurgitation. As clinical adoption continues to rise and new developments emerge, transcatheter mitral valve replacement is poised to offer renewed hope for patients and set new benchmarks in cardiac care.
Key Takeaways: Global Transcatheter Mitral Valve Market
- The global transcatheter mitral valve market is poised for substantial growth, projected to reach USD 1.6 billion by 2024 and USD 3.0 billion by 2034, expanding at a CAGR of 10.8%.
- United States Expected to lead with a CAGR of 12.8% due to expanded CMS coverage for transcatheter edge-to-edge treatments.
- Germany Strong growth anticipated at a CAGR of 10% driven by medical tourism and favorable reimbursement policies.
- China Projected to grow at a CAGR of 11.7% due to high prevalence of rheumatic fever and increasing focus on cardiac health.
- Product Transcatheter mitral valve repair dominates with an 82.4% market share in 2023, offering advantages like improved left ventricular function and reduced complications.
- End User Hospitals hold the largest market share of 36.7% in 2023, driven by increasing cardiac procedures and government investments in healthcare infrastructure.
- Expanded CMS coverage, medical tourism, increasing prevalence of rheumatic diseases, technological advancements, and rising cardiac procedures are key factors propelling market growth.
Get Old Source Offers the Latest Report Editions
Competitive Landscape:
The global transcatheter mitral valve market is primarily dominated by two industry giants: Abbott and Edwards. Both companies are at the forefront of developing groundbreaking technologies aimed at supporting patients suffering from mitral and tricuspid regurgitation.
These companies have secured licenses and patents for their technologies within this domain. However, the expiration of these licenses and patents could impact the future revenues and operating income of these key players.
Recent Developments:
- April 2024: Medtronic plc announced that the one-year results from the SMART study indicate that the Medtronic Evolut™ TAVR platform is the optimal therapy for severe aortic stenosis in patients with a small annulus, particularly women.
- May 2024: The one-year outcomes from the Bionetic-i study demonstrate the safety and effectiveness of iliac artery treatment using BIOTRONIK’s Dynetic-35 cobalt chromium balloon-expandable stent system.
Key Players of Transcatheter Mitral Valve Market:
- HLT Inc
- Coramaze Technologies
- Medtronic
- Biotronik
- NeoChord, Inc.
- Colibri Heart Valve LLC
- Neovasc
- Edwards Lifesciences Corporation
- Abbott Laboratories
- LIVANOVA PLC
Key Segments of Transcatheter Mitral Valve Market:
By Product:
In terms of product, the industry is divided into transcatheter mitral valve replacement and transcatheter mitral valve repair.
By Indication:
In terms of indication, the industry is segregated into mitral stenosis and mitral regurgitation.
By End user:
The industry is classified by end user as hospitals, ambulatory surgical centers and cardiac catheterization laboratories
By Region:
Key countries of North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe and Middle East & Africa have been covered in the report.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
